All In Biotech

Drug Trial Radar · NCT06589713

Effect of Renal Impairment on Enpatoran Pharmacokinetics

Phase 1, Open Label, Single Dose Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Enpatoran in Male and Female Participants

Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

34

Actual

Start

Sep 24, 2024

Primary completion

Apr 13, 2026

Study completion Apr 13, 2026

Sponsor

Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the effect of renal impairment on the pharmacokinetics of enpatoran.

Conditions

  • Renal Impairment

Interventions

  • EnpatoranDrug

    Participants will receive a single oral dose of enpataron tablets once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic (PK) Plasma Concentrations of EnpatoranTime frame: Predose, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, and 48 hours postdose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CRS Clinical Research Services Kiel GmbH

    Kiel, Schleswig-Holstein, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.